What technological revolutions are needed for the most likely curative breakthrough in cancer treatment?

By first-principles thinking, based on what we have been achieved in experimental research and clinical practice, a relatively simple, cost-effective pan-anticancer and mostly curative breakthrough in cancer treatment or theragnostics, i.e. OncoCiDia, has been introduced. Its rationale can be explained below.
 1) The essence of cancer is the heterogeneity of various malignant tumors caused by gene mutations. To conquer all heterogeneous solid malignancies, first we have to homogenize them into a common target so that they can be treated or cured by using by the same drug or therapy, which may allow for safe, effective, broad-spectrum, and precise anti-cancer treatment.

2) The safety and efficacy of iodine-131 in diagnosing and curing thyroid cancer have been a medical consensus for over half a century. However, it has so far been ineffective against other malignant tumors, but implying its powerful capacity.

3) Almost all malignant solid tumors can be caused into partial necrosis by non-invasive chemical drugs such as CA4P or minimally invasive physical ablation such as RFA, though hardly eradicated, leading to tumor regrowth. But the resulted necrosis hare can serve as a perfect common target for all solid cancers, implying the possibility of a pan-anticancer approach.

4) We have discovered necrosis-avid small molecules such as hypericin, which are magnitudes stronger than the in vivo interactions between antibody and antigen or biotin and avidin. 

5) These necrosis-avid compounds can be loaded with iodine-131 to form targeted radiopharmaceuticals to realize a truly curative breakthrough of sequential dual-targeting pan-anticancer theragnostics OncoCiDia. The 8-days decay half-life of iodine-131 with high-energy β-particles of 2 mm penetration distance and low-energy imaging γ-rays enables constant targeted radiotherapy to the remaining cancer cells while monitored by SPECT/CT, usually one episode drug delivery is sufficient. 

6) Besides, in conjunction with cancer liquid biopsy technology, OncoCiDia can cure micro-cancers of various origins with just one treatment, i.e. micro-cancer ablation (MiCAbla).